Sohini Das And Arnab Dutta

Stories by Sohini Das And Arnab Dutta

Covid: How Pfizer plans to resolve cold storage issues in India

Covid: How Pfizer plans to resolve cold storage issues in India

Rediff.com   7 Dec 2020

The company has developed detailed logistical plans and tools to support effective vaccine transport, storage, and temperature monitoring. Sohini Das and Ruchika Chitravanshi report.

Why your mobile phones are likely to cost more

Why your mobile phones are likely to cost more

Rediff.com   3 Dec 2020

With supply of mobile chipsets running dry, manufacturers here are left with no option but to hike prices once again, making it the fourth round of increase in 2020.

How states are preparing for Covid vaccine distribution

How states are preparing for Covid vaccine distribution

Rediff.com   2 Dec 2020

Each state has its own weak areas that need attention. Some states have already identified the gaps and sought the Centre's help. Vinay Umarji, Ishita Ayan Dutt, Samreen Ahmad and Sohini Das report.

How India Inc plans to tap robust rural market

How India Inc plans to tap robust rural market

Rediff.com   30 Nov 2020

While companies have not launched too many products in rural areas of late, easy financing has helped push up demand.

India may get first Covid-19 vaccine by February

India may get first Covid-19 vaccine by February

Rediff.com   30 Nov 2020

The government plans to immunise 30 million people in the first phase, starting February, and by July, the target is to vaccinate 250 million people, reports Sohini Das.

Indian Immunologicals to set up new vaccine plant, raise capacity by 35%

Indian Immunologicals to set up new vaccine plant, raise capacity by 35%

Rediff.com   26 Nov 2020

The company has a pipeline of viral vaccines including Zika, dengue, varicella, as well as a potential Covid-19 inoculation.

Smartphones costing Rs 35,000+ grow 91%

Smartphones costing Rs 35,000+ grow 91%

Rediff.com   26 Nov 2020

E-learning and work from home have forced a section of feature phones users to shift to smartphones.

Micromax wants to give Bharat an option against China

Micromax wants to give Bharat an option against China

Rediff.com   20 Nov 2020

With its new line-up, the firm has managed to touch the right chords, but to regain market share from the established players, Micromax will have to fight a protracted battle.

Slaying the dragon: 71% Indians boycotted Chinese goods this Diwali

Slaying the dragon: 71% Indians boycotted Chinese goods this Diwali

Rediff.com   17 Nov 2020

According to CAIT, the estimated loss to Chinese manufacturers this Diwali could be as high as Rs 40,000 crore.

Serum Institute to keep 200 mn doses of Covid vaccine ready by Jan

Serum Institute to keep 200 mn doses of Covid vaccine ready by Jan

Rediff.com   13 Nov 2020

'SII has started stockpiling the vaccine and now has roughly 40 million doses ready. It is using some of the capacities it had for under development products for the COVID-19 vaccine and by January we will have a capacity to make 100 million doses per month and a stockpile of 200 million doses.'

Online sale of durables nearly doubles this season

Online sale of durables nearly doubles this season

Rediff.com   5 Nov 2020

With consumers staying indoors and e-commerce firms extending their reach to a larger number of pin codes, these giants have snatched a larger share from the offline traders this season.

Pandemic pushes up demand for CT scanners; firms gear up to meet surge

Pandemic pushes up demand for CT scanners; firms gear up to meet surge

Rediff.com   4 Nov 2020

Siemens Healthineers, one of the largest manufacturers of made-in-India CT scanners, has sold 80-100 such machines in the last 45 days. The medical technology firm typically sells 250 machines in a year.

Bharat Biotech starts Covaxin's at-risk manufacture

Bharat Biotech starts Covaxin's at-risk manufacture

Rediff.com   2 Nov 2020

The first vaccine candidate will be an intra-muscular one, followed by intra-dermal and nasal ones, depending on test results.

Latest iPhone 12 sees 25% spike in pre-orders

Latest iPhone 12 sees 25% spike in pre-orders

Rediff.com   31 Oct 2020

According to sources, in spite of coming with higher price tags, so far over 100,000 orders have been placed for iPhone 12 models.

How India's handset makers are planning a comeback

How India's handset makers are planning a comeback

Rediff.com   30 Oct 2020

At least two of them - Lava and Micromax - are arming themselves against the Chinese rivals which made them insignificant in the local market over the past few years.

Why Dr Reddy's had to shut all its units

Why Dr Reddy's had to shut all its units

Rediff.com   25 Oct 2020

Security breach came days after the firm got approval to conduct trials for Covid-19 vaccine candidate Sputnik V.

Chinese smartphones continue to dominate Indian market

Chinese smartphones continue to dominate Indian market

Rediff.com   22 Oct 2020

In spite of being attacked from all corners, a faltering supply chain and negative sentiments soaring high among the local consumers, top Chinese smartphone brands gained market share during the most critical phase - the April-June quarter of this year.

How Modi's SVAMITVA scheme aims to help rural property holders

How Modi's SVAMITVA scheme aims to help rural property holders

Rediff.com   21 Oct 2020

SVAMITVA is a new government project that primarily aims to demarcate abadi areas that includes inhabitant land, inhabited areas contiguous to abadi and wadis/basties in rural areas, using drone surveying technology.

After almost 2 years, Samsung to resume producing TVs in India

After almost 2 years, Samsung to resume producing TVs in India

Rediff.com   15 Oct 2020

Citing unviable duty structure on key components like flat panels and open cell parts, Samsung had shuttered its TV assembly lines in Tamil Nadu in 2018.

Covid-19 impact: Low interest loans likely for vaccine companies

Covid-19 impact: Low interest loans likely for vaccine companies

Rediff.com   10 Oct 2020

While there has been no commitment from the government on the procurement of vaccines, initial volumes, or distribution plans, there is a likelihood that the low interest loans may be made available to these players only when the time to scale up manufacturing arises.